Cognition Therapeutics (CGTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Voting matters and shareholder proposals
Election of two Class II directors, Aaron Fletcher, Ph.D. and Lisa Ricciardi, for a three-year term expiring in 2029 is up for vote.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026 is proposed.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Audit committee and external auditor matters
Proposal to ratify Ernst & Young LLP as the external auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cognition Therapeutics
- Advancing zervimesine for DLB psychosis with strong Phase 2 data and FDA alignment.CGTX
Investor presentation - Net loss improved to $3.9M in Q2 2026, with strong cash position and extended patent protection.CGTXQ2 2026
- Phase II trials showed strong efficacy and safety, with Phase III and partnerships in focus.CGTXLife Sciences Investor Forum
- Directors and auditor were elected by majority vote at a virtual annual meeting, with Q&A after.CGTXAGM 2026
- Oral therapy for Lewy body dementia psychosis shows strong efficacy and safety in phase II trials.CGTXJefferies Global Healthcare Conference 2026
- Advancing zervimesine for DLB psychosis with strong efficacy, safety, and regulatory support.CGTXInvestor presentation
- Q1 2026 net loss narrowed to $4.6M as R&D costs fell, with $31.2M cash and clinical progress.CGTXQ1 2026
- Board recommends director elections and auditor ratification, highlighting governance and ESG.CGTXProxy filing
- CT1812 slowed cognitive decline by up to 108% in patients with low plasma p-tau217, supporting phase 3 trials.CGTXStudy Update